COMPLIMENTARY CE CREDIT
Thursday, March 14th, 5:00 - 6:00 PM ET
Program Overview
With the approval of 2 new entities, recent advances in enzyme replacement therapy (ERT) have created a paradigm shift in which healthcare providers (HCPs) have gone from only being able to use a single agent to being able to choose a treatment from multiple available options. Furthermore, the increasing adoption of newborn screening is allowing for greater appreciation of the early manifestations of late-onset Pompe disease (LOPD) and the opportunity to intervene earlier in the disease course. This activity will explore the new understanding around LOPD symptom onset and the efficacy of next-generation treatments to modify disease progression. Case-based scenarios that explore treatment initiation, how to monitor disease progression with the emerging biomarkers and patient-reported outcomes, strategies for multidisciplinary care that include shared-decision making, and considerations around treatment switching will be discussed.
Target Audience
This activity is intended for neuromuscular specialists, neurologists, clinical geneticists, genetic counselors, inherited metabolic disease/lysosomal storage disorder specialists, as well as other HCPs involved in the diagnosis and management of LOPD.
Educational Objectives
Upon completion of this activity, the learner should be able to:
- Recognize the clinical impact that the progressive, multisystemic pathology of LOPD has on treatment initiation and effectiveness
- Evaluate clinical data, considering varying efficacy and safety outcomes, on ERT/enzyme stabilizer therapy and secondg eneration ERT in LOPD
- Integrate varying measures of disease severity and progression, including patient-reported outcomes, into individualized treatment decision-making for LOPD
- Identify strategies to support shared decision-making as part of treatment selection and management decisions in LOPD
- Develop individualized LOPD treatment plans that include next-generation therapies and consider the latest clinical data, holistic measures of disease progression, and patient preferences
- The Impact of Our Evolving Understanding of LOPD on Treatment Goals
- Evaluating the Utility of Next-generation LOPD-Modifying Therapy
- Delivering Comprehensive Care for LOPD in an Evolving Treatment Era
- Q&A and Closing Remarks
FACULTY
Priya S. Kishnani, MD, MBBS
C.L. and Su Chen Professor of Pediatrics
Medical Director, YT and Alice Chen
Pediatric Genetics and Genomics Center
Division Chief, Medical Genetics
Professor of Molecular Genetics and Microbiology
Duke University Medical Center
Durham, North Carolina
Professor Mark Roberts, BSc, MBChB, FRCP, MD
Consultant Neurologist
Greater Manchester Neurosciences Unit
Salford Royal NHS Foundation Trust
Salford, United Kingdom
Professor Dr. med. Benedikt Schoser, FEAN
Friedrich Baur Institute
Neurological Clinic and Polyclinic
LMU Clinic
Ludwig-Maximilians-University Munich
Munich, Germany
Disclosure
It is the
policy of AKH Inc. to ensure independence, balance, objectivity, scientific
rigor, and integrity in all of its continuing education activities. The author
must disclose to the participants any significant relationships with ineligible
companies whose products or devices may be mentioned in the activity or with the
commercial supporter of this continuing education activity. Identified
conflicts of interest are mitigated by AKH prior to accreditation of the
activity. AKH planners and reviewers have no relevant financial relationships
to disclose.
CRITERIA
FOR SUCCESS
Certificates of completion will be awarded based on the participant’s
attendance and submission of the activity evaluation/claim credit form. You
must participate in the entire activity to receive credit. There is no fee to
participate in this activity. If you have questions about this activity, please
contact AKH Inc. at tbrignoni@akhcme.com.
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Physician Assistants — 1.0 AAPA Category 1 CME credits
- NSGC CEU — Category 2
All other health care professionals completing this course will be issued a statement of participation.
In support of improving patient care,
this activity has been planned and implemented by AKH Inc., Advancing Knowledge
in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing
Knowledge in Healthcare is jointly accredited by the Accreditation Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy
Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a
maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Physician Assistants
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Genetic Counselor CEUs
To
apply for National Society of Genetic Counselors Category 2 CEU, please go to
https://www.nsgc.org/Education-and-Events/Continuing-Education-Unit-CEU-Information
Provider Information
This program is jointly provided by AKH Inc., Advancing Knowledge in Healthcare
and Catalyst Medical Education, LLC
Commercial Support:
This activity is supported by an educational grant from Amicus Therapeutics, Inc.
Disclaimer
This
course is designed solely to provide the healthcare professional with
information to assist in his/her practice and professional development and is
not to be considered a diagnostic tool to replace professional advice or
treatment. The course serves as a general guide to the healthcare professional,
and therefore, cannot be considered as giving legal, nursing, medical, or other
professional advice in specific cases. AKH Inc. specifically disclaim
responsibility for any adverse consequences resulting directly or indirectly
from information in the course, for undetected error, or through participant's
misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are
investigational and/or unapproved by the FDA. Please refer to the official
prescribing information for each product for discussion of approved
indications, contraindications, and warnings.
AKH Privacy Policy (link:
https://akhcme.com/akhcme/pages/privacy)